CM
SMMT icon

Caption Management’s Summit Therapeutics SMMT Stock Holding History

Caption Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.46M Buy
+100,000
New +$1.77M 0.01% 1004
2025
Q4 		– Sell
-28,264
Closed -$532K – 2027
2025
Q3 		$584K Sell
28,264
-238,991
-89% -$5.8M ﹤0.01% 1266
2025
Q2 		$5.69M Buy
+267,255
New +$6.09M 0.06% 363

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Caption Management's SMMT Position: Q2 2026 in Review

Caption Management opened a new position in Summit Therapeutics (SMMT) in Q2 2026: 100,000 shares worth $1.46M. The stake represents 0.01% of the portfolio and ranks #1004 among its holdings. This is a return to the name: Caption Management previously reported a position in SMMT as recently as Q3 2025.

Caption Management first reported a position in SMMT in Q2 2025 and has held it in 3 quarters since. The position peaked at $5.69M in Q2 2025. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Caption Management held 100,000 shares of Summit Therapeutics worth $1.46M as of Q2 2026.
  • Summit Therapeutics was a new Caption Management position in Q2 2026.
  • Summit Therapeutics made up 0.01% of Caption Management's portfolio in Q2 2026, its #1004 holding.
  • Caption Management first reported a position in Summit Therapeutics in Q2 2025 and has held it in 3 quarters since.
  • Caption Management's Summit Therapeutics position peaked at $5.69M in Q2 2025.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.